Evolutionarily conserved chaperone-mediated proteasomal degradation of a disease-linked aspartoacylase variant

Sarah Gersing, Yong Wang, Martin Grønbæk-Thygesen, Caroline Kampmeyer, Lene Clausen, Claes Andréasson, Amelie Stein, Kresten Lindorff‐Larsen, Rasmus Hartmann‐PetersenbioRxiv 2020 · DOI

TL;DR

This paper investigates why a specific mutation (C152W) in the aspartoacylase (ASPA) enzyme leads to Canavan disease, despite appearing stable in lab tests. They discovered that this variant is rapidly degraded by the cell's protein quality control system, involving chaperones like Hsp70 and Hsp110, and this pathway is conserved in human cells. This suggests targeting these chaperones could be a therapeutic strategy for Canavan disease.

What Problem Does This Paper Address?

Canavan disease is a severe neurodegenerative disorder linked to mutations in the ASPA gene. One such mutation, C152W, causes a significant drop in ASPA protein levels in cells, leading to the disease. However, biophysical experiments suggest that the C152W variant has similar thermal stability to the normal (wild-type) ASPA. This creates a puzzle: if the protein is stable, why is it present at such low levels? This paper aims to unravel the degradation pathway of the C152W variant and understand how this leads to reduced protein levels and, consequently, Canavan disease.

Methods

The researchers employed a multi-pronged approach:

  • Yeast-based reporter system: They engineered yeast cells with a fusion protein combining ASPA (wild-type or C152W) with a reporter (Ura3-HA-GFP). Yeast growth in a uracil-deficient medium directly correlated with the abundance of the functional ASPA fusion protein. This allowed them to screen for factors affecting ASPA stability.
  • Proteasome inhibition: They used bortezomib (BZ), a proteasome inhibitor, to see if blocking protein degradation could rescue the reduced levels of the C152W variant.
  • Cycloheximide (CHX) treatment: This drug inhibits protein synthesis, allowing researchers to measure the degradation rate of existing proteins.
  • Solubility assays and microscopy: They assessed whether the C152W variant formed aggregates and examined its cellular localization.
  • Molecular Dynamics (MD) simulations: These simulations were used to investigate the structural dynamics of wild-type and C152W ASPA at the atomic level to detect subtle conformational changes.
  • Chaperone and E3 ligase knockdowns/mutations: They systematically knocked down or mutated key components of the protein quality control (PQC) system in yeast (e.g., Hsp70, Hsp110, Ubr1) and observed the effect on ASPA C152W stability.
  • Human cell experiments: They validated their findings in human U2OS cells by using similar techniques (siRNA knockdowns, proteasome inhibition, Western blotting).

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • The "stable but degraded" paradox: The C152W variant is not globally destabilized in a way that's easily detectable by standard biophysical methods, yet it's rapidly cleared by the cell. This highlights the sensitivity of cellular protein quality control systems.
  • De novo folding is key: Instead of a stable misfolded state, the C152W mutation likely interferes with the process of folding during protein synthesis (de novo folding), leading to transiently exposed degradation signals.
  • Chaperone network is crucial: The degradation of ASPA C152W is not a solitary event but relies on a complex interplay of chaperones (Hsp70, Hsp110) and E3 ubiquitin ligases (like Ubr1).
  • Conservation across species: The same chaperone-mediated degradation pathway observed in yeast is also active in human cells, making yeast a powerful model for studying human disease mechanisms.
  • Therapeutic potential of targeting chaperones: The findings strongly suggest that modulating the activity of chaperones like Hsp110 could be a viable strategy to stabilize disease-causing protein variants.

Key Results

  • Yeast experiments:
    • ASPA C152W showed significantly reduced growth in uracil-deficient media compared to wild-type ASPA, indicating lower protein levels.
  • This reduction was due to increased proteasomal degradation, as confirmed by CHX treatment and rescue by the proteasome inhibitor bortezomib.
  • MD simulations showed no substantial global structural differences between wild-type and C152W ASPA.
  • Knocking out or inhibiting key chaperones (Hsp70, Hsp110) and E3 ligases (Ubr1) stabilized ASPA C152W.
  • ASPA C152W formed more aggregates than wild-type ASPA, and Hsp104 played a role in disaggregating these.
  • Human cell experiments:
    • ASPA C152W also showed reduced stability and increased turnover in human U2OS cells.
  • This degradation was ubiquitin-dependent and proteasome-mediated.
  • Inhibiting Hsp70 or knocking down Hsp110 homologs (HSPH1, HSPA4) stabilized ASPA C152W.
  • HSPH1 was shown to interact with the 26S proteasome, and its knockdown led to increased ubiquitination of ASPA C152W.

Limitations and Future Work

  • Mechanism of degron exposure: While the paper proposes transient exposure of a buried degron or delayed de novo folding as the cause, the exact molecular mechanism by which C152W leads to this exposure requires further investigation.
  • Mammalian E3 ligases: The study focused on yeast E3 ligases and did not extensively examine specific mammalian E3 ligases involved in ASPA degradation, though it suggests human Ubr1 orthologs and CHIP might be involved.
  • Therapeutic targeting of Hsp110: While Hsp110 is proposed as a therapeutic target, the paper notes that targeting it to stabilize C152W might lead to insoluble protein accumulation. Further research is needed to optimize this approach and explore its efficacy for other ASPA variants.
  • Broader ASPA variant analysis: The study focused on C152W. Investigating the degradation pathways of other disease-linked ASPA variants using methods like VAMP-seq is suggested for a comprehensive understanding.

Summary updated

Abstract

Abstract Canavan disease is a severe progressive neurodegenerative disorder that is characterized by swelling and spongy degeneration of brain white matter. The disease is genetically linked to polymorphisms in the aspartoacylase ( ASPA ) gene, including the substitution C152W. ASPA C152W is associated with greatly reduced protein levels in cells, yet biophysical experiments suggest a wild-type like thermal stability. Here, we examine the stability and degradation pathway of ASPA C152W. When we expressed ASPA C152W in Saccharomyces cerevisiae , we found a decreased steady state compared to wild-type ASPA as a result of increased proteasomal degradation. However, molecular dynamics simulations of ASPA C152W did not substantially deviate from wild-type ASPA, indicating that the native state is structurally preserved. Instead, we suggest that the C152W substitution prevents ASPA from reaching its stable native conformation, presumably by impacting on de novo folding. Systematic mapping of the protein quality control components acting on misfolded and aggregation-prone species of C152W, revealed that the degradation is highly dependent on the molecular chaperone Hsp70, its co-chaperone Hsp110 as well as several quality control E3 ubiquitin-protein ligases, including Ubr1. In human cells, ASPA C152W displayed increased proteasomal turnover that was similarly dependent on Hsp70 and Hsp110. We propose that Hsp110 is a potential therapeutic target for misfolding ASPA variants that trigger Canavan disease due to excessive degradation.
BibTeX
@misc{gersing2020evolutionarily,
  author = {Sarah Gersing and Yong Wang and Martin Grønbæk-Thygesen and Caroline Kampmeyer and Lene Clausen and Claes Andréasson and Amelie Stein and Kresten Lindorff‐Larsen and Rasmus Hartmann‐Petersen},
  title = {{Evolutionarily conserved chaperone-mediated proteasomal degradation of a disease-linked aspartoacylase variant}},
  year = {2020},
  doi = {10.1101/2020.09.04.283028},
  howpublished = {bioRxiv},
}
Figure